Spark Biopharma
Clinical trials sponsored by Spark Biopharma, explained in plain language.
-
New drug shows promise for lung scarring disease in early trial
Disease control Recruiting nowThis study tests an experimental drug called SB17170 in 30 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing problems. The goal is to see if the drug can improve lung function compared to a placebo over 12 weeks. Participants will …
Phase: PHASE2 • Sponsor: SPARK Biopharma • Aim: Disease control
Last updated May 17, 2026 01:47 UTC
-
New hope for tough tumors: experimental drug SB17170 enters human testing
Disease control Recruiting nowThis early-phase trial tests a new drug, SB17170, in about 50 adults with advanced solid tumors that have stopped responding to standard care. The main goals are to find the safest dose and check for side effects. Researchers will also measure how the drug moves through the body …
Phase: PHASE1 • Sponsor: SPARK Biopharma • Aim: Disease control
Last updated May 12, 2026 13:40 UTC